Special Issue

Dysregulation of Cyclic AMP and Cyclic PIP Synthesis: Implications for Disease and Advances in Therapeutic Development

Message from the Guest Editor

"The reversible phosphorylation of proteins is a key control mechanism that regulates cellular processes such as metabolism, cell division, neurotransmission". The task of the two intracellular regulators, cyclic AMP and cyclic PIP (prostaglandylinositol cyclic phosphate) is to control the equilibrium between the phospho- and de-phospho-form of key enzymes and, thus, to control the activity of these enzymes. The dysregulation of protein phosphorylation is known/discussed to be related, for instance, to illnesses such as Alzheimer's disease, chronic inflammatory diseases, cancer, and type-2 diabetes. Generally, we divide the signal transduction into three levels: First, the receptor to which a hormone or neurotransmitter binds: then second, the point of interest of this Special Issue, the synthesis of intracellular regulators, which spread the signal inside the cell; and third the resultant regulatory changes. The goal of the Special Issue is to combine newer research results related to the topic of broken signal transduction in this publication.

Guest Editor

Dr. Heinrich K Wasner

BioReg Biopharm, Technology Innovation Laboratory, University of Illinois at Chicago, Chicago, IL 60612, USA

Deadline for manuscript submissions

25 January 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/224393

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

